Lymphangioleiomyomatosis

Revision as of 13:31, 26 September 2011 by WikiBot (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Lymphangioleiomyomatosis
CT scan of a lung with LAM.
OMIM 606690
DiseasesDB ddb30755
MeSH D018192

WikiDoc Resources for Lymphangioleiomyomatosis

Articles

Most recent articles on Lymphangioleiomyomatosis

Most cited articles on Lymphangioleiomyomatosis

Review articles on Lymphangioleiomyomatosis

Articles on Lymphangioleiomyomatosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lymphangioleiomyomatosis

Images of Lymphangioleiomyomatosis

Photos of Lymphangioleiomyomatosis

Podcasts & MP3s on Lymphangioleiomyomatosis

Videos on Lymphangioleiomyomatosis

Evidence Based Medicine

Cochrane Collaboration on Lymphangioleiomyomatosis

Bandolier on Lymphangioleiomyomatosis

TRIP on Lymphangioleiomyomatosis

Clinical Trials

Ongoing Trials on Lymphangioleiomyomatosis at Clinical Trials.gov

Trial results on Lymphangioleiomyomatosis

Clinical Trials on Lymphangioleiomyomatosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lymphangioleiomyomatosis

NICE Guidance on Lymphangioleiomyomatosis

NHS PRODIGY Guidance

FDA on Lymphangioleiomyomatosis

CDC on Lymphangioleiomyomatosis

Books

Books on Lymphangioleiomyomatosis

News

Lymphangioleiomyomatosis in the news

Be alerted to news on Lymphangioleiomyomatosis

News trends on Lymphangioleiomyomatosis

Commentary

Blogs on Lymphangioleiomyomatosis

Definitions

Definitions of Lymphangioleiomyomatosis

Patient Resources / Community

Patient resources on Lymphangioleiomyomatosis

Discussion groups on Lymphangioleiomyomatosis

Patient Handouts on Lymphangioleiomyomatosis

Directions to Hospitals Treating Lymphangioleiomyomatosis

Risk calculators and risk factors for Lymphangioleiomyomatosis

Healthcare Provider Resources

Symptoms of Lymphangioleiomyomatosis

Causes & Risk Factors for Lymphangioleiomyomatosis

Diagnostic studies for Lymphangioleiomyomatosis

Treatment of Lymphangioleiomyomatosis

Continuing Medical Education (CME)

CME Programs on Lymphangioleiomyomatosis

International

Lymphangioleiomyomatosis en Espanol

Lymphangioleiomyomatosis en Francais

Business

Lymphangioleiomyomatosis in the Marketplace

Patents on Lymphangioleiomyomatosis

Experimental / Informatics

List of terms related to Lymphangioleiomyomatosis

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Lymphangioleiomyomatosis (LAM) is the result of disorderly smooth muscle proliferation throughout the bronchioles, alveolar septa, perivascular spaces, and lymphatics, resulting in the obstruction of small airways (leading to pulmonary cyst formation and pneumothorax) and lymphatics (leading to chylous pleural effusion). LAM occurs in a sporadic form, which only affects females, who are usually of childbearing age. LAM also occurs in patients who have tuberous sclerosis.

Cause

Sporadic LAM only affects women.

The proliferating smooth muscle that occurs in the type of LAM seen in patients with tuberous sclerosis (TSC-LAM) has been shown to represent clones of the smooth muscle in those patients' renal angiomyolipomas. Thus it is believed to represent metastases of this "benign" tumor. There is a female preponderance to TSC-LAM. (reference: Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes, Chromosomes & Cancer. Dec. 2003. 38(4):376-81)

Radiography

With LAM, there is diffuse replacement of the pulmonary parenchyma by thin-walled cysts measuring 2-20 mm in diameter, with equal involvement of upper and lower lung zones. On chest X-rays, superimposition of the cysts gives a reticulonodular pattern of interstitial lung disease. High-resolution CT of the chest is both more specific for the diagnosis, as well as better able to assess the degree of pulmonary involvement.

Prognosis

Exact data on survival rates are difficult to collect because LAM is often misdiagnosed as asthma or other more common diseases, and may not be correctly identified until it is in an advanced condition. A comprehensive study of all known British LAM patients found that out of 21 patients that had been observed for 15 years or more since diagnosis, 18 were still alive; and 11 of 12 patients that had been observed for 20 years or more were alive. (reference: Johnson SR, et al Survival and disease progression in UK patients with lymphangioleiomyamatosis Thorax. 2004. 59:800-803)

Complications

Treatment

The association of LAM with women of childbearing age suggests that hormonal stimulation plays a role in the disease process, and several approaches to treatment involve diminishing the effect of estrogen. At one time or another, therapeutic approaches have included

No therapy is clearly efficacious, and all have undesirable side-effects. There is some evidence which shows that tamoxifen may actually cause worsening of LAM in some patients.[1][2]

When pulmonary function deteriorates to the point where oxygenation is inadequate, lung transplantation is usually performed. Following lung transplant (usually unilateral), LAM patients have Kaplan-Meier estimators (survival curves) similar to other lung transplant patients.

Doxycycline has been proposed as a treatment with minimal side-effects.[3]

Sirolimus is being tested for the treatment of LAM. The MILES Trial (Multicenter International LAM Efficacy of Sirolimus Trial) is now underway. The first site, the University of Cincinnati, is open for enrollment. The National Institutes of Health will open enrollment soon. The MILES Trial is randomized, double-blinded, and placebo-controlled. The objective of the Trial is to determine if sirolimus has a beneficial effect on lung function in LAM patients.

Research

LAM Treatment Alliance

The LAM Foundation (US)

Support

LAM Action (UK)

The LAM Foundation (US)

References

  1. Clemm C, Jehn U, Wolf-Hornung B, Siemon G, and Walter G (1987). "Lymphangiomyomatosis: a report of three cases treated with tamoxifen". Klin Wochenschr. 65: 391–393.
  2. Yu J, Astrinidis A, Howard S, and Henske E (2004). "Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways". Am J Physiol Lung Cell Mol Physiol. 286: L694–L700.
  3. Moses MA, Harper J, Folkman J (2006). "Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs". New Engl J Med. 354 (24): 2621&ndash, 22.

Template:SIB

nl:Lymfangioleiomyomatose ur:سیالہ وعائی ہمعضلومہ


Template:WikiDoc Sources